Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Anti-CD19 therapy may help treat SLE and NMOSD.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

The cat improved with treatment but had kidney issues from long-term allopurinol use.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Using fat-derived stem cells with the drug meglumine antimoniate can help control skin disease and reduce parasites in mice with leishmaniasis.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Upadacitinib improved multiple immune-related conditions in one patient.

Baricitinib improved hair loss and arthritis in a lupus patient.

Belimumab effectively controls SLE disease activity and reduces steroid use.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Promising cancer treatments were found, but the manufacturer closed.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.